My PD Story
Danielle Schmitt, PhD
2026 Impact Award
Visualizing in Real Time How Parkinson’s Affects PINK1 and Mitochondria
While many Parkinson’s disease (PD) cases arise from environmental causes, young-onset PD (YOPD) is more often caused by genetic variants. These DNA changes cause certain proteins to not work properly, leading to the progressive loss of fragile dopamine neurons in the brain. PD GENEration: Powered by the Parkinson's Foundation, our international research initiative offering genetic testing and counseling at no cost for people living with PD, has found 12% of people with PD have one of the seven primary PD genetic variants.
One of the primary PD genetic variants is called PINK1, affecting the PINK1 protein. This protein is important for monitoring the health of mitochondria, the powerhouses of cells. Developing treatments targeting PINK1 has been difficult since it is a small and dynamic protein that is difficult to see within cells.
Danielle Schmitt, PhD, recipient of a Parkinson’s Foundation Impact Award, has developed a breakthrough biochemical tool that can help researchers visualize PINK1 activity in real time, a feat that has not been possible before. Being able to study PINK1 in this new and advanced way could improve our ability to design effective PD treatments for those with a PINK1 variant.
“This research provides us with an unprecedented ability to observe PINK1 in action, opening doors to discoveries that weren’t possible before and potentially leading to new Parkinson’s therapies.” – Dr. Schmitt
When mitochondria in a cell become damaged or dysfunctional, PINK1 signals the cell to recycle and replace them. The PINK1 genetic variant prevents the protein from doing its job, leading to a build-up of broken mitochondria that stresses and ultimately shuts down the cell.
Previously, scientists were only able to study PINK1 in indirect or aggregated ways. Researchers could take individual pictures of its activity but could never capture how exactly it operates inside the cell in real time. Dr. Schmitt’s new tool, called PINK1-SPARK, acts like watching a video: it allows researchers like herself and her team to watch PINK1 work live, seeing how it interacts with the mitochondria and other cell components.
From her lab at the University of California, Los Angeles, Dr. Schmitt will use PINK1-SPARK to study PINK1 behavior in normal neurons and those with misfolded alpha-synuclein, simulating PD. Scientists have hypothesized that alpha-synuclein interferes with PINK1 in the cell — now Dr. Schmitt will be able to see if that is the case.
Dr. Schmitt will also utilize PINK1-SPARK to screen for new potential drugs that effectively activate PINK1. Compounds that can increase PINK1 activity could be useful PD therapeutics, improving mitochondrial function and overcoming the disruptions caused by alpha-synuclein and genetic variants. With this breakthrough new tool in hand, a variety of new therapeutic avenues targeting PINK1 are now open for discovery.
“I am very grateful for the support of the Parkinson's Foundation to be able to use our unique tools to study Parkinson's,” said Dr. Schmitt. “We hope to turn our discoveries in the lab into meaningful therapies that can make a difference for people with PD.”
Meet more Parkinson’s researchers! Explore our My PD Stories featuring PD researchers.
Related Materials
More Stories
from the Parkinson's community